STEVOSANDBOX
UAT

EBSCO Auth Banner

Let's find your institution. Click here.

Test GIN Import

ALL#ABCDEFGHIJKLMNOPQRSTUVWXYZ
101 - 110 of 136 results found

Treatment of Anemia in Patients with Heart Disease: A Clinical Practice Guideline From the American College of Physicians

MeSH Terms

Hematinics (D27.505.954.502.543); Injections; Intravenous (E02.319.267.082.750); Iron (D01.552.544.412); Iron (D01.268.956.287); Iron (D01.268.556.412); Anemia; Iron-Deficiency (C15.378.071.196.300); Anemia; Iron-Deficiency (C18.452.565.100); Coronary Disease (C14.907.585.250); Coronary Disease (C14.280.647.250); Erythrocyte Transfusion (E02.095.135.140.275); Exercise Tolerance (G11.427.680.270); Heart Failure (C14.280.434)

Guideline Contact
Amir Qaseem (aqaseem@acponline.org)
Record Publish Year
2013
Publication Scope
management
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
ACP (US)
Publication Year
2013

Treatment of Brain Metastases

MeSH Terms

Neoplasm Metastasis (C04.697.650)

Guideline Contact
guidelines@asco.org
Expected Publication Date
2021
Publication Scope
treatment
Countries of Application
United States
Guideline Publication Status
Development
Languages
English
Authors
ASCO (US)

Treatment of Hypertension in Adults Over Age 60 to Higher vs. Lower Targets: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians

MeSH Terms

Blood Pressure (G09.330.380.076); Pharmacologic Actions (D27.505); Angiotensin-Converting Enzyme Inhibitors (D27.505.519.389.745.085); Angiotensin Receptor Antagonists (D27.505.519.162); Antihypertensive Agents (D27.505.954.411.162); Calcium Channel Blockers (D27.505.954.411.192); Calcium Channel Blockers (D27.505.519.562.249); Adrenergic beta-1 Receptor Antagonists (D27.505.696.577.050.200.200.100); Adrenergic beta-1 Receptor Agonists (D27.505.696.577.050.100.200.100); Adrenergic beta-1 Receptor Antagonists (D27.505.519.625.050.200.200.100); Adrenergic beta-1 Receptor Agonists (D27.505.519.625.050.100.200.100); Adrenergic beta-2 Receptor Agonists (D27.505.519.625.050.100.200.200); Adrenergic beta-2 Receptor Antagonists (D27.505.519.625.050.200.200.200); Adrenergic beta-2 Receptor Agonists (D27.505.696.577.050.100.200.200); Adrenergic beta-2 Receptor Antagonists (D27.505.696.577.050.200.200.200); Adrenergic beta-3 Receptor Agonists (D27.505.519.625.050.100.200.300); Adrenergic beta-3 Receptor Agonists (D27.505.696.577.050.100.200.300); Adrenergic beta-3 Receptor Antagonists (D27.505.519.625.050.200.200.300); Adrenergic beta-3 Receptor Antagonists (D27.505.696.577.050.200.200.300); Hypertension (C14.907.489); Blood Pressure (E01.370.600.875.249)

Guideline Contact
Amir Qaseem (aqaseem@acponline.org)
Date for Review
17/01/2022
Record Publish Year
2017
Publication Scope
management;treatment
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
AAFP (US);ACP (US)
Publication Year
2017

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

MeSH Terms

Vitamin D (D04.808.812.768); Women (M01.975); Osteoporosis (C05.116.198.579); Pharmacologic Actions (D27.505); Therapeutic Uses (D27.505.954); Alendronate (D02.705.429.500.100); Peptide Hormones (D06.472.699); Peptide Hormones (D12.644.548); Teriparatide (D06.472.699.590.850); Teriparatide (D12.644.548.587.850); Calcitonin (D06.472.699.150); Calcitonin (D12.644.400.095); Calcitonin (D12.644.548.150); Calcitonin (D12.776.641.650.095); Estrogen Replacement Therapy (E02.319.452.150); Selective Estrogen Receptor Modulators (D27.505.696.399.450.360.827); Selective Estrogen Receptor Modulators (D06.347.360.827); Raloxifene (D02.455.426.559.389.150.700.900.775); Osteoporosis; Postmenopausal (C05.116.198.579.610); Calcium (D01.268.552.100); Calcium (D01.552.539.288)

Guideline Contact
Amir Qaseem (aqaseem@acponline.org)
Date for Review
6/6/22
Record Publish Year
2017
Publication Scope
prevention;treatment
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
ACP (US)
Publication Year
2017

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

MeSH Terms

Multiple Myeloma (C04.557.595.500); Stem Cell Transplantation (E04.936.225.687); Maintenance Chemotherapy (E02.319.509)

Guideline Contact
guidelines@asco.org
Record Publish Year
2019
Expected Publication Date
April 1, 2019
Publication Scope
management;treatment
Countries of Application
Canada;United States
Guideline Publication Status
Published
Languages
English
Authors
ASCO (US)
Publication Year
2019

Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline

MeSH Terms

Urinary Bladder Neoplasms (C04.588.945.947.960)

Guideline Contact
guidelines@asco.org
Record Publish Year
2017
Publication Scope
management
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
ASCO (US);ASTRO (US)
Publication Year
2017